ES2559429T3 - Anticuerpos anti-NGF humanizados - Google Patents

Anticuerpos anti-NGF humanizados Download PDF

Info

Publication number
ES2559429T3
ES2559429T3 ES10003283.8T ES10003283T ES2559429T3 ES 2559429 T3 ES2559429 T3 ES 2559429T3 ES 10003283 T ES10003283 T ES 10003283T ES 2559429 T3 ES2559429 T3 ES 2559429T3
Authority
ES
Spain
Prior art keywords
cdr
amino acid
acid sequence
humanized anti
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10003283.8T
Other languages
English (en)
Inventor
Antonino Cattaneo
Sonia Covaceuszach
Doriano Lamba
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Research BV
Original Assignee
AbbVie Research BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Research BV filed Critical AbbVie Research BV
Application granted granted Critical
Publication of ES2559429T3 publication Critical patent/ES2559429T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Neurology (AREA)

Abstract

Un anticuerpo anti-NGF humanizado o un fragmento del mismo que mantiene la actividad de unión a NGF, donde el anticuerpo anti-NGF humanizado comprende: (a) una región variable de la cadena pesada que tiene una primera CRD que comprende la secuencia de aminoácidos GFSLTNNNVN, una segunda CDR que comprende la secuencia de aminoácidos GVWAGGATDYNSALKS, y una tercera CDR que comprende la secuencia de aminoácidos DGGYSSSTLYAMDA; y (b) una región variable de la cadena ligera que tiene una primera CDR que comprende la secuencia de aminoácidos RASEDIYNALA, una segunda CDR que comprende la secuencia de aminoácidos HT, y una tercera CDR que comprende la secuencia de aminoácidos QHYFHYPRT; donde la región marco de la región variable de la cadena pesada es al menos el 85% idéntica a la región marco de SEC ID Nº: 19; y la región marco de la región variable de la cadena ligera es al menos el 85% idéntica a la región marco de SEC ID Nº: 20; y donde el aminoácido de la región variable de la cadena pesada que corresponde a la posición 67 de SEC ID Nº: 19 es Phe, y donde el aminoácido de la región variable de la cadena pesada que corresponde a la posición 71 de SEC ID Nº: 19 es Arg; y donde el aminoácido de la región variable de la cadena ligera que corresponde a la posición 46 de SEC ID Nº: 20 es 20 Leu, donde el aminoácido de la región variable de la cadena ligera que corresponde a la posición 50 de SEC ID Nº: es Asn, donde el aminoácido de la región variable de la cadena ligera que corresponde a la posición 51 de SEC ID Nº: 20 es Thr, donde el aminoácido de la región variable de la cadena ligera que corresponde a la posición 52 de SEC ID Nº: 20 es Asp, donde el aminoácido de la región variable de la cadena ligera que corresponde a la posición 53 de SEC ID Nº: 20 es Thr, donde el aminoácido de la región variable de la cadena ligera que corresponde a la posición 54 de SEC ID Nº: 20 es Leu, y donde el aminoácido de la región variable de la cadena ligera que corresponde a la posición 87 de SEC ID Nº: 20 es Phe.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
<210> 14 5 <211> 78
<212> ADN
<213> Homo sapiens
<400> 14 10
imagen7
<210> 15
<211> 75
<212> ADN
<213> Homo sapiens
<400> 15
imagen8
<210> 16
<211> 75
<212> ADN
<213> Homo sapiens
<400> 16
imagen9
30
<210> 17
<211> 122
<212> PRT
<213> Homo sapiens 35
<400> 17
24
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19

Claims (1)

  1. imagen1
ES10003283.8T 2003-12-24 2004-12-23 Anticuerpos anti-NGF humanizados Active ES2559429T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000601A ITRM20030601A1 (it) 2003-12-24 2003-12-24 Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
ITRM20030601 2003-12-24

Publications (1)

Publication Number Publication Date
ES2559429T3 true ES2559429T3 (es) 2016-02-12

Family

ID=34708536

Family Applications (2)

Application Number Title Priority Date Filing Date
ES09008366T Active ES2377535T3 (es) 2003-12-24 2004-12-23 Anticuerpos anti-NGF humanizados
ES10003283.8T Active ES2559429T3 (es) 2003-12-24 2004-12-23 Anticuerpos anti-NGF humanizados

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES09008366T Active ES2377535T3 (es) 2003-12-24 2004-12-23 Anticuerpos anti-NGF humanizados

Country Status (20)

Country Link
US (7) US8296079B2 (es)
EP (4) EP2308894A3 (es)
JP (4) JP4652341B2 (es)
CN (2) CN101724070B (es)
AT (1) ATE534665T1 (es)
AU (4) AU2004303633B2 (es)
BR (1) BRPI0418202A (es)
CA (2) CA2551796C (es)
CY (2) CY1112611T1 (es)
DK (3) DK2138512T3 (es)
ES (2) ES2377535T3 (es)
HK (2) HK1139697A1 (es)
HU (1) HUE027475T2 (es)
IL (2) IL176495A (es)
IT (1) ITRM20030601A1 (es)
PL (2) PL2138512T3 (es)
PT (2) PT2218737E (es)
SI (2) SI2138512T1 (es)
WO (1) WO2005061540A2 (es)
ZA (1) ZA200605200B (es)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
BRPI0607486B8 (pt) 2005-03-03 2021-05-25 Immunomedics Inc anticorpo humanizado l243 contra hla-dr presente nas células hladr+,composição farmacêutica, kit e uso dos referidos anticorpos.
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
ITRM20050332A1 (it) 2005-06-24 2006-12-25 Lay Line Genomics Spa Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore.
ZA200805400B (en) * 2005-12-21 2009-09-30 Micromet Ag Pharmaceutical compositions with resistance to soluble CEA
US8309088B2 (en) * 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
KR101709495B1 (ko) 2007-08-10 2017-02-23 리제너론 파아마슈티컬스, 인크. 인간 신경성장인자에 대한 고친화성 인간 항체
JP2011509650A (ja) 2008-01-11 2011-03-31 株式会社ジーンテクノサイエンス ヒト化抗−α９インテグリン抗体及びその使用
KR101782857B1 (ko) * 2008-02-04 2017-09-28 레이 라인 지노믹스 에스.피.에이. 항―ｔｒｋａ 항체 및 이의 유도체
EP2282769A4 (en) 2008-04-29 2012-04-25 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
US9109026B2 (en) 2008-06-03 2015-08-18 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
CA2726087A1 (en) 2008-06-03 2009-12-10 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
KR20110031369A (ko) 2008-07-08 2011-03-25 아보트 러보러터리즈 프로스타글란딘 ｅ2 이원 가변 도메인 면역글로불린 및 이의 용도
BRPI0922224A2 (pt) * 2008-12-08 2016-08-02 Vm Pharma Llc composições de inibidores de proteína tirosina quiinase receptora.
ES2613730T3 (es) * 2008-12-18 2017-05-25 Erasmus University Medical Center Rotterdam Animales transgénicos no humanos que expresan anticuerpos humanizados y su uso
CN102741287B (zh) 2009-02-17 2015-02-18 Ucb制药公司 对人ox40具有特异性的抗体分子
EP2448970B1 (en) 2009-05-04 2014-07-09 Abbott Research B.V. Antibodies against nerve growth factor (ngf) with enhanced in vivo stability
CN102459628A (zh) 2009-05-13 2012-05-16 基酶有限公司 抗人cd52 免疫球蛋白
PE20121531A1 (es) * 2009-10-15 2012-12-22 Abbott Lab Inmunoglobulinas con dominio variable dual
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
JP2013522313A (ja) 2010-03-17 2013-06-13 アボツト・リサーチ・ベー・フエー 抗神経成長因子（ｎｇｆ）抗体組成物
CN103298834A (zh) 2010-08-03 2013-09-11 Abbvie公司 双重可变结构域免疫球蛋白及其用途
ES2910305T3 (es) 2010-08-19 2022-05-12 Zoetis Belgium S A Anticuerpos anti-NGF y su uso
CA2809433A1 (en) 2010-08-26 2012-03-01 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9783602B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
GB201114858D0 (en) * 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
GB2528811A (en) * 2011-05-06 2016-02-03 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
CA2834983C (en) * 2011-05-06 2020-11-17 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
CA2835094C (en) * 2011-05-06 2020-12-22 David Gearing Anti-nerve growth factor antibodies and methods of preparing and using the same
HUE057288T2 (hu) * 2011-05-06 2022-04-28 Zoetis Services Llc Idegi növekedési faktor elleni ellenanyagok és eljárások elõállításukra és alkalmazásukra
GB2528401A (en) * 2011-05-06 2016-01-20 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
SG194793A1 (en) * 2011-05-06 2013-12-30 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
GB2505352B (en) * 2011-05-06 2016-01-27 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
WO2013009582A1 (en) 2011-07-12 2013-01-17 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
ME02944B (me) 2011-08-11 2018-04-20 Astellas Pharma Inc Novo antitelo protiv humanog ngf
US8926978B2 (en) 2011-10-25 2015-01-06 Anaptysbio, Inc. Antibodies directed against nerve growth factor (NGF)
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
EP2797955A2 (en) 2011-12-30 2014-11-05 AbbVie Inc. Dual variable domain immunoglobulins against il-13 and/or il-17
EP2858501A4 (en) 2012-05-22 2015-12-09 Merck Sharp & Dohme TRK-A KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
EP2859018B1 (en) 2012-06-06 2021-09-22 Zoetis Services LLC Caninized anti-ngf antibodies and methods thereof
US20150183885A1 (en) * 2012-06-08 2015-07-02 Glenmark Pharmaceuticals S.A. Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof
EA201492163A1 (ru) * 2012-06-08 2015-08-31 Гленмарк Фармасьютикалс С.А. ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К TrkA, СОДЕРЖАЩИЕ АМИНОКИСЛОТНЫЕ ЗАМЕНЫ
EP2674439B1 (en) 2012-06-13 2017-02-01 Rottapharm Biotech S.r.l. Anti-TrkA antibodies, derivatives and uses thereof
CN104884472B (zh) 2012-11-01 2021-10-15 艾伯维公司 抗-vegf/dll4双重可变结构域免疫球蛋白及其用途
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
AR095199A1 (es) * 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
WO2014144280A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
WO2015039333A1 (en) 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2015039334A1 (en) 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
CN103965357B (zh) 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
US10221250B2 (en) 2014-01-13 2019-03-05 Valerion Therapeutics, Llc Internalizing moieties
CN106029614B (zh) 2014-02-05 2019-05-31 Vm肿瘤药物有限责任公司 化合物的组合物及其用途
WO2015143653A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143652A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143654A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
MA41097A (fr) * 2014-12-05 2017-10-10 Glenmark Pharmaceuticals Sa Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
EP3085709B1 (en) 2014-12-28 2019-08-21 Genor Biopharma Co., Ltd Humanized anti-human rankl antibody, pharmaceutical composition and use thereof
AU2016210544B2 (en) 2015-01-23 2020-12-10 Gvk Biosciences Private Limited Inhibitors of TrkA kinase
WO2016161572A1 (en) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
TWI706959B (zh) * 2015-05-22 2020-10-11 日商安斯泰來製藥股份有限公司 新穎抗人類ＮＧＦ抗體Ｆａｂ片段
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
JP6889328B2 (ja) 2017-07-31 2021-06-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 三次元構造に基づくヒト化方法
US20200399348A1 (en) * 2018-02-20 2020-12-24 Emory University HPV Proteins, Antibodies, and Uses in Managing Abnormal Epithelial Cell Growth
AR114110A1 (es) 2018-02-28 2020-07-22 Lilly Co Eli Anticuerpo anti-trka
KR20200130696A (ko) 2018-03-12 2020-11-19 조에티스 서비시즈 엘엘씨 항-ngf 항체 및 이의 방법
KR102265434B1 (ko) * 2019-08-20 2021-06-15 주식회사 케어젠 피부 미백 활성을 갖는 펩타이드 및 이의 용도
CN114981303B (zh) * 2019-09-13 2024-01-23 安徽俊义医疗管理咨询有限公司 人源化抗Claudin18.2（CLDN18.2）抗体
CN117003868B (zh) * 2020-04-17 2024-04-16 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
CN116003590A (zh) * 2020-08-06 2023-04-25 熙源安健医药（上海）有限公司 抗ngf抗体及其抗原结合片段、其制备方法和应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230691A (en) * 1978-05-23 1980-10-28 The Massachusetts General Hospital Nerve growth factor antibody and process
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
SE465573B (sv) 1989-03-14 1991-09-30 Lope Medicine Ab Nervtillvaextfaktorpeptider, motsvarande antikroppar och foerfarande foer bestaemning av nativ nervtillvaextfaktor
EP0737746A3 (en) 1989-12-01 1996-10-23 Pharming B.V. Production of recombinant polypeptides by bovine species and transgenic methods
US5147294A (en) * 1990-10-01 1992-09-15 Trustees Of Boston University Therapeutic method for reducing chronic pain in a living subject
WO1992008483A1 (en) 1990-11-13 1992-05-29 The Children's Medical Center Corporation CONTROLLING β-AMYLOID RELATED NEURONAL DEGENERATION BY ANTAGONIZING NGF-EFFECTED NEURONAL ACTIVITY
AU9164991A (en) 1990-11-30 1992-06-25 Abbott Laboratories Immunoassay and monoclonal antibodies useful for detecting truncated nerve growth factor receptor
DK0590058T3 (da) * 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
JPH07505767A (ja) * 1992-02-06 1995-06-29 シェリング・コーポレーション ヒトインターロイキン−５に対するヒト化モノクローナル抗体の設計，クローン化および発現
EP0578515A3 (en) * 1992-05-26 1995-05-10 Bristol Myers Squibb Co Humanized monoclonal antibodies.
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9402331D0 (en) 1994-02-07 1994-03-30 Univ Mcgill Nerve growth factor structural analogs and their uses
US5747060A (en) 1996-03-26 1998-05-05 Euro-Celtique, S.A. Prolonged local anesthesia with colchicine
DE19732928C2 (de) 1997-07-31 2000-05-18 Gruenenthal Gmbh Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel
US6652864B1 (en) 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
IT1306704B1 (it) 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
US7273964B1 (en) * 1999-08-06 2007-09-25 Scuola Internazionale Superiore Di Studi Avanzati Non-human transgenic animals for the study of neurodegenerative syndromes
EP1265605B1 (en) * 2000-01-18 2006-09-27 McGILL UNIVERSITY Pharmaceutical compositions comprising beta-turn peptidomimetic cyclic compounds
US6548062B2 (en) 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
CA2402596A1 (en) * 2000-03-16 2001-09-27 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
FR2807660A1 (fr) 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
AU2002259305A1 (en) 2001-05-25 2002-12-09 Cornell Research Foundation, Inc. High affinity ligand for p75 neurotrophin receptor
CA2448956C (en) * 2001-05-30 2017-10-03 Genentech, Inc. Anti-ngf antibodies for the treatment of various disorders
SE0102067D0 (sv) 2001-06-11 2001-06-11 A & Science Invest Ab Prevention of neovascularization of intervertebral discs and/or of tissues with local inflammation
CA2454587C (en) * 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
JP2003231687A (ja) * 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
AU2003284010A1 (en) 2002-10-04 2004-05-04 Rinat Neuroscience Corp. Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
WO2005000194A2 (en) 2002-10-08 2005-01-06 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
UA80447C2 (en) * 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
CA2501626A1 (en) * 2002-10-08 2004-04-22 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering a nerve growth factor antagonist and compositions containing the same
WO2004056385A2 (en) 2002-12-20 2004-07-08 Neuronicon Aps Modulation of activity of neurotrophins
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
CN102746399B (zh) 2002-12-24 2016-03-02 里纳特神经***学公司 抗ngf抗体及其使用方法
US20040131515A1 (en) 2003-01-03 2004-07-08 Alexanian Ara J. Material heat treatment system and method statement regarding federally sponsored research or development
WO2004065560A2 (en) 2003-01-18 2004-08-05 Rinat Neuroscience Corp. Methods of screening for modulators of nerve growth factor
AU2004213044A1 (en) 2003-02-19 2004-09-02 Rinat Neuroscience Corp. Methods for treating pain by administering a nerve growth factor antagonist and an NSAID and compositions containing the same
WO2005019266A2 (en) 2003-07-15 2005-03-03 Amgen Inc. Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
WO2005044293A2 (en) 2003-11-07 2005-05-19 Lay Line Genomics S.P.A. Compositions able to prevent neurodegenerative processes and methods of assaying the same
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
US7522822B2 (en) 2004-01-06 2009-04-21 Robert Trujillo Halogen lamp assembly with integrated heat sink
SI1732949T1 (sl) 2004-04-07 2010-05-31 Rinat Neuroscience Corp Postopki za zdravljenje bolečine kostnega raka zdajanjem antagonista živčnega rastnega faktorja
ITRM20040212A1 (it) 2004-04-30 2004-07-30 Lay Line Genomics Spa Animale transgenico non umano come modello per malattie neurodegenerative e per la loro diagnosi precoce.
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
BRPI0606933B8 (pt) 2005-01-24 2021-05-25 Cambridge Antibody Tech Limited membro de ligação específico isolado para fator de crescimento de nervos, molécula de anticorpo isolado, composição e uso de um membro de ligação específico
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
ITRM20050332A1 (it) 2005-06-24 2006-12-25 Lay Line Genomics Spa Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore.
US7290968B1 (en) 2006-03-06 2007-11-06 Shih-Chang Wu Extension fixture for turning tool
AU2007338791B2 (en) 2006-12-21 2014-03-13 Amgen Inc Stable buffered formulations containing polypeptides
CA2688275A1 (en) 2007-05-31 2008-12-04 Genmab A/S Stable igg4 antibodies
KR101709495B1 (ko) * 2007-08-10 2017-02-23 리제너론 파아마슈티컬스, 인크. 인간 신경성장인자에 대한 고친화성 인간 항체
US8309088B2 (en) * 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
AU2008337100B2 (en) * 2007-12-17 2013-02-28 Pfizer Limited Treatment of interstitial cystitis
EP2141593A1 (en) 2008-07-02 2010-01-06 Telefonaktiebolaget L M Ericsson (Publ) Requirement dependent allocation of hardware units to applications
US20120294913A1 (en) 2010-02-03 2012-11-22 Morinage Milk Industry Co., Ltd Method for manufacturing aloe powder
JP2013522313A (ja) 2010-03-17 2013-06-13 アボツト・リサーチ・ベー・フエー 抗神経成長因子（ｎｇｆ）抗体組成物

Also Published As

Publication number Publication date
SI2138512T1 (sl) 2012-04-30
AU2012261567A1 (en) 2013-01-10
JP2015110601A (ja) 2015-06-18
CN1906212A (zh) 2007-01-31
US20110191872A1 (en) 2011-08-04
SI2218737T1 (sl) 2016-03-31
AU2016269485A1 (en) 2017-01-05
EP2218737A3 (en) 2011-05-11
CN101724070A (zh) 2010-06-09
HK1139697A1 (en) 2010-09-24
AU2004303633B2 (en) 2011-12-08
AU2009245889A1 (en) 2010-01-07
EP1709076A2 (en) 2006-10-11
AU2012261567B2 (en) 2016-09-08
IL176495A0 (en) 2006-10-05
EP2218737A2 (en) 2010-08-18
CA2551796A1 (en) 2005-07-07
ATE534665T1 (de) 2011-12-15
ZA200605200B (en) 2009-08-26
US20110104164A1 (en) 2011-05-05
US20150218264A1 (en) 2015-08-06
US8877491B2 (en) 2014-11-04
DK2218737T3 (en) 2016-02-29
AU2004303633A1 (en) 2005-07-07
CN1906212B (zh) 2013-07-17
WO2005061540A3 (en) 2005-09-22
CA2688944C (en) 2015-04-07
WO2005061540A2 (en) 2005-07-07
CA2688944A1 (en) 2005-07-07
PT2218737E (pt) 2016-03-18
CN101724070B (zh) 2015-07-08
JP2012126726A (ja) 2012-07-05
CA2551796C (en) 2015-11-03
PL2218737T3 (pl) 2016-09-30
IL176495A (en) 2014-05-28
US20090300780A1 (en) 2009-12-03
US20110105728A1 (en) 2011-05-05
JP4652341B2 (ja) 2011-03-16
ES2377535T3 (es) 2012-03-28
JP2008500274A (ja) 2008-01-10
US20110105727A1 (en) 2011-05-05
HUE027475T2 (en) 2016-09-28
JP2009291211A (ja) 2009-12-17
HK1147268A1 (zh) 2011-08-05
EP2308894A2 (en) 2011-04-13
DK1709076T3 (da) 2012-08-27
PL2138512T3 (pl) 2012-09-28
EP2138512B8 (en) 2012-03-14
US8246956B2 (en) 2012-08-21
US20140316113A1 (en) 2014-10-23
ITRM20030601A1 (it) 2005-06-25
EP2138512B1 (en) 2011-11-23
AU2009245889B2 (en) 2012-12-13
PT2138512E (pt) 2012-03-05
EP2218737B1 (en) 2015-12-02
IL220128A0 (en) 2012-07-31
CY1112611T1 (el) 2016-02-10
BRPI0418202A (pt) 2007-04-17
US8257710B2 (en) 2012-09-04
EP2138512A1 (en) 2009-12-30
CY1117303T1 (el) 2017-04-26
DK2138512T3 (da) 2012-02-27
EP2308894A3 (en) 2011-05-11
EP1709076B1 (en) 2012-05-23
US8296079B2 (en) 2012-10-23

Similar Documents

Publication Publication Date Title
ES2559429T3 (es) Anticuerpos anti-NGF humanizados
ES2527961T3 (es) Anticuerpos monoclonales humanos para CD70
IN2009KN02655A (es)
NO20061070L (no) Antistoffer mot parathyoidhormon (PTH) og anvendelser derav
DK1706424T3 (da) FC-region varianter
CY1114851T1 (el) Il-1βητα δεσμευτικα αντισωματα και θραυσματα αυτων
CY1107989T1 (el) Ανασυνδυασμενα αντισωματα της ανθρωπινης ιντepλευκινης-1 βητα
ATE476994T1 (de) Antikörper gegen gpnmb und ihre verwendungen
NO20054836L (no) Nogo-reseptorbindingsprotein
DK1461428T3 (da) Fremgangsmåde til at fremstille hybridantistoffer
TR200200735T2 (tr) CTLA-4 için insan monoklonal antikorları
DE60229799D1 (de) Aufzeichnungsverfahren für fluoreszierende Bilder.
ATE382683T1 (de) Monoklonales antikörper gegen das hcv kernantigen
WO2005047325A3 (en) Monkey immunoglobulin sequences
CY1117395T1 (el) Il-1βητα δεσμευτικα αντισωματα και θραυσματα αυτων
DE60040010D1 (de) Ein Verfahren zum Auffinden vom Prostatakrebs
SE0103129D0 (sv) Monoclonal antibodies against creatine kinase CKMB2
RU2007143819A (ru) Способ отбора крупного рогатого скота по воспроизводительной способности